TAM
CORT icon

Tocqueville Asset Management’s Corcept Therapeutics CORT Stock Holding History

Tocqueville Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-70,000
Closed -$1.35M – 806
2017
Q3 		$1.35M Buy
+70,000
New +$1.04M 0.02% 495
2016
Q4 		– Sell
-65,800
Closed -$428K – 817
2016
Q3 		$428K Buy
+65,800
New +$383K 0.01% 653

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Tocqueville Asset Management's CORT Position: Q4 2017 in Review

Tocqueville Asset Management sold out of Corcept Therapeutics (CORT) in Q4 2017, closing a stake of 70,000 shares — an estimated $1.35M sold.

Tocqueville Asset Management first reported a position in CORT in Q3 2016 and held it in 2 quarters. The position peaked at $1.35M in Q3 2017. 190 funds tracked by Wall St. Rank hold CORT as of Q4 2017.

  • Tocqueville Asset Management reported no remaining Corcept Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Tocqueville Asset Management sold 70,000 Corcept Therapeutics shares in Q4 2017, an estimated $1.35M.
  • Tocqueville Asset Management first reported a position in Corcept Therapeutics in Q3 2016 and held it in 2 quarters.
  • Tocqueville Asset Management's Corcept Therapeutics position peaked at $1.35M in Q3 2017.
  • 190 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2017.

Based on Tocqueville Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.